Background {#Sec1}
==========

Kidney calculi are a common urinary system disease, and their incidence is increasing annually \[[@CR1]\]. In the clinical guideline of the American College of Physicians, the prevalence of kidney calculi in men and women was 13% and 7%, respectively, and the 5-year recurrence rate of untreated kidney calculi was 35--50% \[[@CR2]\]. Correspondingly, the high recurrence rate yielded a certain economic burden to patients with kidney calculi. Kidney calculi are caused by abnormal accumulation of some crystalline substances, such as calcium, oxalic acid, uric acid, and cystine, and organic matrices, such as matrix A and acid mucopolysaccharide, in the kidney. Most kidney calculi are composed of calcium; calcium oxalate stones are the most common, accounting for 74.8% of all cases of stones \[[@CR3]\]. In response to increasing incidence of kidney calculi, various interventions have been performed to prevent the occurrence of stones, including dietary interventions and medical treatments \[[@CR4]--[@CR6]\]. Among them, thiazide diuretics are the commonly used drugs for preventing recurrent kidney calculi \[[@CR7], [@CR8]\]. However, some clinical trials reported that thiazide diuretics had no significant prophylactic effect compared with the placebo \[[@CR9], [@CR10]\]. We also found that the recommended grade of thiazide diuretics to prevent recurrent kidney calculi was not consistent among guidelines \[[@CR2], [@CR7], [@CR8], [@CR11]\]. Further, no meta-analyses have yet been conducted to prove that thiazide diuretics can prevent recurrent renal calculi. Therefore, we performed a systematic review and meta-analysis of clinical trials that investigated thiazide diuretics for the prevention of recurrent renal calculi to provide evidence-based medical data for use in clinical practice. We aimed to evaluate the effect and safety of thiazide diuretics on recurrent kidney calculi patients, comparing the incidence of recurrent kidney calculi and the 24-h urinary calcium level with that of placebo or no medication group in randomized controlled trials (RCTs).

Methods {#Sec2}
=======

Trial search {#Sec3}
------------

Two researchers independently searched all studies with keywords of thiazide diuretics and kidney calculi published in the PubMed, EMBASE, and Cochrane Library databases. The following search terms were used: "kidney stones", "kidney calculi", "renal calculi", "nephrolith", "thiazide diuretics", "sodium chloride cotransporter inhibitors". The article search was limited by study design of RCTs. The search was performed until December 31, 2018. In addition, the references of the included studies were also retrieved to supplement the relevant research, including gray literatures (e.g., clinical trials). When the opinions of the two researchers differed, a third researcher was consulted. When there were other languages used, we sought help from linguists.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The inclusion and exclusion criteria for the studies were determined prior to data extraction. The inclusion criteria included the following: (1) RCTs with thiazide diuretic administration as the intervention and placebo or no medication as the control condition; (2) patients with renal calculi or hypercalciuria as the study subjects; and (3) test indicators including at least one of the following: number of patients with new stones, 24-h urinary calcium level, 24-h urinary oxalate level, and serum calcium level. Conversely, the exclusion criteria included the following: (1) non-RCTs; (2) RCTs without a treatment group or placebo group; (3) trials with incomplete or no data available; and (4) other study types, e.g., abstract, case report, and review.

Risk of bias assessment {#Sec5}
-----------------------

Two investigators independently searched for studies using different search strategies and screened for studies that met the inclusion criteria. The researchers evaluated the quality of the included RCTs using the Cochrane Library risk bias assessment tool. The seven items used to assess bias in each trial included random sequence generation, allocation concealment, double blindness of participants and trial performers, blindness of outcome assessment, incomplete outcome data, selective reporting, and other biases. Each quality item was divided and categorized into high risk, undefined risk, and low risk. The quality of the included trials was rated as low quality, high quality, or medium quality according to the following criteria: (1) if random sequence generation or allocation concealment was assessed to be of a high risk, the trial would be considered to be of low quality regardless of the risk of other projects; (2) if random sequence generation and allocation concealment were assessed to be of a low risk, and all other items were assessed to be of a low or an undefined risk, the test would be of high quality; and (3) if the tests did not meet the high risk or low risk criteria, the quality of the trial was considered moderate \[[@CR12]\].

Data extraction {#Sec6}
---------------

Two investigators extracted the following data from the included studies: primary author; year of publication; sex, age; sample size; interventions; control group; number of lost visits; and follow-up time. When the trials were greater than two sets or had multi-factor designs, we only extracted content relevant to this study.

Statistical analysis {#Sec7}
--------------------

We performed a meta-analysis and calculated the relative ratio (RR), risk difference (RD), standardized mean difference (SMD), and 95% confidence interval (CI). The pooled RR and RD were used to estimate the efficiency of thiazide diuretics on recurrent kidney calculi by using Mantel--Haenszel method. The pooled SMD were used to evaluate the effect of thiazide diuretics on 24-h urinary calcium level by using inverse variance method. We used *I*^2^ statistics to assess statistical heterogeneity. An *I*^2^ value of 0--25% indicates no significant heterogeneity; 26--50%, low heterogeneity; 51--75%, moderate heterogeneity; and \> 75%, high heterogeneity \[[@CR13]\]. Data were pooled using the fixed-effects model when the *I*^2^ value was \< 50%; data were pooled using the random-effects model when the *I*^2^ value was \> 50%. The test level was set at *α *= 0.05; *P* values of 0.05 were considered to indicate that the difference was statistically significant. We used the Review Manager 5.2 software (The Cochrane Collaboration, Oxford, UK) to perform the meta-analysis and forest plot analysis and the Stata 13.0 software (Stata Corp, College Station, TX) to conduct the publication bias test (Egger's test). Evidence quality grading was performed for each outcome measure with reference to the GRADE criteria, and recommendations for the prevention of recurrent kidney calculi using thiazide diuretics were reassessed on the basis of a decision table formed according to the recommendations of the WHO Handbook for Guideline Development \[[@CR14]\]. To assess whether the efficacy of thiazide diuretics in preventing recurrent kidney calculi is related to their clinical features, we performed a subgroup analysis based on the duration of drug action; we also did a subgroup analysis based on quantitative methods of 24-h urinary calcium. For the robustness of the results, we conducted a sensitivity analysis.

Results {#Sec8}
=======

Study search {#Sec9}
------------

A total of 103 records were searched according to the search strategy (Additional file [1](#MOESM1){ref-type="media"}: Table S1), and 28 of them were related to thiazide diuretics for preventing kidney calculi after screening of the titles and abstracts (Fig. [1](#Fig1){ref-type="fig"}). Eight of them were reviews; seven investigated non-thiazide diuretics compared with a control condition; two reported failure to reduce the incidence of renal calculi; two were meta-analyses; three were non-RCTs; and six reported reduction of the occurrence of kidney calculi. We finally included eight RCTs conducted on thiazide diuretics \[[@CR9], [@CR10], [@CR15]--[@CR20]\].Fig. 1Literature search and screening process

Characteristics and risk of bias {#Sec10}
--------------------------------

Among the included articles, there were seven studies published in English language \[[@CR9], [@CR10], [@CR15]--[@CR17], [@CR19], [@CR20]\] and one in Spanish language \[[@CR18]\]. Seven of them had patients with recurrent calcium stones as the subjects \[[@CR9], [@CR10], [@CR16]--[@CR20]\]; one trial had patients with idiopathic hypercalciuria as the subjects \[[@CR15]\]. Table [1](#Tab1){ref-type="table"} shows the specific characteristics and data of the studies included. The patients and experimenters were both blinded to the study data. Seven papers did not report the generation of random sequence \[[@CR9], [@CR10], [@CR15]--[@CR18], [@CR20]\] and were of moderate quality. One study used the medical record number to assign patients into groups \[[@CR19]\], which was of low quality. The overall quality of the studies was moderate (Fig. [2](#Fig2){ref-type="fig"}).Table 1Characteristics of the included trials and participantsAuthorYearPatientsGender (M/F)Mean age (year)SampleEvents/total (intervention)Events/total (placebo)Drugs (intervention)Drugs (control)Lost visitsPercent of lost visitsFollow-up (month)Borghi et al. \[[@CR20]\]1993Recurrent calcium stonesI: 18/7C: 20/5I: 46.5C: 42.8403/199/21IndapamideNo treatment1020%36Brocks et al. \[[@CR10]\]1981Recurrent calcium stonesNR16--49625/335/29BendroflumethiazidePlacebo0048Ettinger et al. \[[@CR19]\]1988Recurrent calcium stonesNRT: L 49.8, H 49.3C: 48.9736/4214/31ChlorthalidonePlaceboNRNR36Fernández-Rodríguez et al. \[[@CR18]\]2006Recurrent calcium stonesNRNR10016/5028/50HydrochlorothiazideNo treatment0036Laerum et al. \[[@CR17]\]1984Recurrent calcium stones38/12T: 45.8C: 42.7485/2312/25Hydrochlorothiazide + KClPlacebo24%12--51Mortensen et al. \[[@CR16]\]1986Recurrent kidney stonesAll male20--49220/124/10Bendroflumethiazide + KClPlacebo518.5%72Ohkawa et al. \[[@CR15]\]1992Calcium stones with hypercalciuriaI: 45/37C: 52/41I: 48.7C: 46.917511/8241/93TrichlormethiazideNo treatment3516.7%6--68Scholz et al. \[[@CR9]\]1982Recurrent calcium calculiI: 14/11C: 17/9I: 46C: 41516/256/26HydrochlorothiazidePlacebo35.6%12*I* intervention group, *C* control group, *NR* not reported, *L* low dose group, *H* high dose group, *KCl* potassium chlorideFig. 2Risk of bias summary for included studies

Incidence of recurrent stone events {#Sec11}
-----------------------------------

There were 286 cases of patients with recurrent kidney calculi in the thiazide diuretic groups and 52 cases of new stones, accounting for 18.2% of all patients; conversely, there were 285 cases in the placebo and untreated groups and 119 cases of new stones, accounting for 41.2% of all patients. The pooled RR for the incidence of renal calculi in the thiazide diuretic groups was 0.44 (95% CI 0.33--0.58, *P *\< 0.0001, *I*^2^= 21%; fixed-effects model; Fig. [3](#Fig3){ref-type="fig"}); the pooled RD was − 0.23 (95% CI − 0.30 to − 0.16, *P *\< 0.0001, *I*^2^= 43%; fixed-effects model; Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Meta-analysis of the incidence of stones in the thiazide diuretic group versus placebo groupFig. 4Risk difference forest plot of stone incidence in thiazide diuretic group versus placebo group

Twenty-four-hour urinary calcium level {#Sec12}
--------------------------------------

The pooled SMD for the 24-h urinary calcium level was − 18.59 (95% CI − 25.11 to − 12.08, *P *\< 0.0001, *I*^2^= 99%; random-effects model; Fig. [5](#Fig5){ref-type="fig"}). Furthermore, Mortensen et al. \[[@CR16]\] reported that the 24-h urinary calcium level of seven patients in their thiazide diuretic group was reduced by 20--25%; none of their control group patients had a urinary calcium level reduction of \> 20%.Fig. 5SMD forest plot of 24-h urinary calcium level in thiazide diuretic group versus placebo group

Subgroup analyses {#Sec13}
-----------------

The subgroup analysis showed that there was no significant difference in the incidence of recurrent renal calculi between short-acting \[[@CR9], [@CR17], [@CR18]\] and long-acting thiazide diuretics \[[@CR10], [@CR15], [@CR16], [@CR19], [@CR20]\] (*P *= 0.05; Fig. [6](#Fig6){ref-type="fig"}). Subgroup analysis revealed that there was a significant difference between 24-h urinary calcium tested by using calcium mass (mg) and the ratio with creatinine (mol/mol) (*P *\< 0.00001, Fig. [7](#Fig7){ref-type="fig"}).Fig. 6Subgroup analysis of thiazide diuretics based on duration of drug actionFig. 7Subgroup analysis of 24-h urinary calcium level

Sensitivity analysis {#Sec14}
--------------------

The sensitivity analysis showed that the results did not change significantly after changing the fixed-effects model to the random-effects model (Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}).Fig. 8Meta-analysis of the incidence of stones by random-effects model in the thiazide diuretic group versus placebo groupFig. 9Risk difference forest plot of stone incidence by random-effects model in thiazide diuretic group versus placebo group

Adverse reactions {#Sec15}
-----------------

Borghi et al. \[[@CR20]\] reported that two patients in their thiazide diuretic group did not complete the study because of the development of hypotension and hypokalemia; Ettinger et al. \[[@CR19]\] reported that 41.5% of the patients in their thiazide diuretic group withdrew from the study owing to intolerance of thiazide diuretics (presence of fatigue, dizziness, and muscle symptoms); Laerum and Larsen \[[@CR17]\] reported that two patients in their thiazide diuretic group withdrew owing to the development of hypokalemia or gout and three patients withdrew owing to the presence of mild fatigue and indigestion; Ohkawa et al. \[[@CR15]\] mentioned that six patients in their thiazide diuretic group developed dizziness; two patients, weakness; and one patient, general malaise; and Scholz et al. reported that one patient in their thiazide diuretic group and another patient in their placebo group withdrew owing to the development of side effects. Further, 11 patients in their thiazide diuretic group complained of fatigue, nausea, and hypotension during treatment; however, the symptoms were not severe enough to cause treatment interruption \[[@CR9]\].

Publication bias {#Sec16}
----------------

Egger's test was performed to analyze the incidence of stone events in the patients with recurrent renal calculi treated with thiazide diuretics. The analysis revealed a *P* value of 0.855.

GRADE rating {#Sec17}
------------

The quality of evidence for thiazide diuretics in reducing the incidence of kidney calculi was low; that in reducing the 24-h urinary calcium level among the patients with recurrent renal calculi was moderate (Table [2](#Tab2){ref-type="table"}). Further, the quality of evidence for short-acting and long-acting thiazide diuretics in reducing the incidence of kidney calculi was low (Table [3](#Tab3){ref-type="table"}).Table 2The evidence quality for thiazide diuretics reducing the incidence of kidney stones and 24-h urinary calcium levelQuality assessmentNo of patientsEffectQualityImportanceNo of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsUCa of thiazide diureticsPlaceboRelative (95% CI)AbsoluteThiazide diuretics VS placebo in 24-h UCa 4Randomized trialsNo serious risk of biasNo serious inconsistencyNo serious indirectnessSerious^a^None145171--SMD 18.59 lower (25.11 to 12.08 lower)ModerateImportantThiazide diuretics VS placebo in incidence of new kidney stones 8Randomized trialsNo serious risk of biasSerious^b^No serious indirectnessSerious^a^None52/286 (18.2%)119/285 (41.8%)--418 fewer per 1000 (from 418 fewer to 418 fewer)LowCritical*UCa* urinary calcium^a^The sample size is not large enough and the event rate is not high enough^b^The outcome of 2 studies is no effectTable 3The evidence quality for short-acting and long-acting thiazide diuretics reducing the incidence of kidney stonesQuality assessmentNo of patientsEffectQualityImportanceNo of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsThiazide diureticsPlacebo in recurrent renal calculusRelative (95% CI)AbsoluteSubgroup---short-acting 3Randomized trialsNo serious risk of biasSeriousNo serious indirectnessSerious^a,b^None27/98 (27.6%)46/101 (45.5%)See comment182 fewer per 1000 (from 50 fewer to 310 fewer)LowImportant48%192 fewer per 1000 (from 53 fewer to 326 fewer)Subgroup---long-acting 5Randomized trialsNo serious risk of biasSerious^a,b^No serious indirectnessSerious^a,b^None25/188 (13.3%)73/184 (39.7%)See comment262 fewer per 1000 (from 179 fewer to 349 fewer)LowImportant42.9%283 fewer per 1000 (from 193 fewer to 378 fewer)^a^The outcome of one study is no effect^b^The sample size is not large enough

Decision form of recommendations {#Sec18}
--------------------------------

The overall strength of recommendation for the prevention of recurrent renal calculi using thiazide diuretics was not recommended (Table [4](#Tab4){ref-type="table"}).Table 4General recommendation strength of thiazide diuretics preventing recurrent renal stonesFactorDecision makingQuality of the evidence(The higher the quality of the evidence, the more likely a strong recommendation is warranted.)LowBalance of benefits versus harms and burdens(The larger the difference between the benefits and harms, the more likely a strong recommendation is warranted. The smaller the net benefit and the lower the certainty for that benefit, the more likely a conditional recommendation is warranted.)Benefits and harms are balancedValues and preferences(The greater the variability or uncertainty in values and preferences, the more likely a conditional recommendation is warranted.)Major variabilityResource use(The higher the costs of an intervention, that is, the more resources consumed, the more likely a conditional recommendation is warranted.)Moderate resource-intensiveOverall recommended strengthLow ↑?

Discussion {#Sec19}
==========

Satisfactory treatment outcomes have not yet been obtained for kidney calculi, and their recurrence rate remains a concern \[[@CR21]--[@CR24]\]. Previously, multiple RCTs and reviews have reported a decreased incidence of recurrent kidney calculi with diet control (e.g., high fluid intake and calcium intake limitation) and thiazide diuretic, alkali citrate, and allopurinol administration. Herein, the overall efficacy of thiazide diuretics in reducing the incidence of recurrent renal calculi was limited when compared to the placebo and untreated groups and the pooled RD with 95% CI was − 0.23 (− 0.30 to − 0.16). The quality of evidence was low owing to the insufficient samples and the inconsistent results among the studies when the GRADE criteria were used to assess the incidence of stone events. This result considerably decreased our expectation of the efficacy of thiazide diuretics in reducing the incidence of recurrent kidney calculi.

We reviewed the clinical guidelines and found that the 2016 updated edition of the Canadian Urological Association guidelines considered thiazide diuretics as a highly recommended drug for preventing recurrent kidney calculi (level of evidence: 1--3 and grade A--B recommendation, based on the Oxford levels of evidence and grades of recommendation). However, the grade according to the American College of Physicians guidelines was weak (grade: weak recommendation, moderate-quality evidence).

In addition to concerns regarding stone events, we also observed a decrease in the serum potassium level and an increase in the uric acid level in some thiazide diuretic groups among the eight studies. Further, 3.7--20% of the patients in the thiazide diuretic groups withdrew from the trials owing to the development of adverse reactions (e.g., hypokalemia, elevated uric acid levels, and abnormal blood glucose and cholesterol levels). Clinically, the main adverse reactions of thiazide diuretics are as follows: (1) water and electrolyte disturbance, such as hypokalemia and hyponatremia; (2) cardiovascular problems, such as blood volume insufficiency and orthostatic hypotension; (3) gastrointestinal reactions, such as anorexia, nausea, gastric irritation, and constipation; (4) central nervous system problems, such as dizziness, paresthesia, and headache; and (5) abnormalities in related metabolic indicators, such as hyperglycemia and elevated total cholesterol levels \[[@CR25]--[@CR27]\]. Makam et al. \[[@CR28]\] showed that 14.3% of thiazide users and 6.0% of non-users had adverse reactions (serum sodium level of \< 135 mmol/L; serum potassium level of \< 3.5 mmol/L; and estimated glomerular filtration rate reduction by \> 25% compared with that at baseline) (*P *\< 0.05). In the ALLHAT trial, the incidence of newly diagnosed diabetes was 17.1% in patients with metabolic syndrome after using chlorthalidone for 4 years; that in patients without metabolic syndrome was 7.7% (*P *\< 0.05) \[[@CR29]\].

However, the patients' compliance was poor. Dauw et al. \[[@CR30]\] found that when patients with kidney calculi were treated with a single prophylactic drug, the proportion of patients in the thiazide diuretic groups who followed the doctor's advice was only 42.5%. Even in the presence of cardiovascular diseases (e.g., hypertension), patients in the thiazide diuretic groups were equally less docile (42%) \[[@CR31]\].

Taken together, thiazide diuretics yielded several adverse reactions, and the patients' compliance was low. Based on the decision table formed by the recommendation in the WHO Handbook for Guideline Development and combined with the degree of benefits for patients with kidney calculi, patients' compliance, adverse reactions caused by long-term medication, and economic burden, thiazides are not recommended for use in preventing recurrent kidney calculi.

Our study also has some limitations: (1) although we searched each database using keywords, not all relevant documents were included, such as unpublished literature; (2) most of the studies included have been conducted several years ago; (3) the kidney calculi investigated in this study were all calcium stones. Whether thiazide diuretics have any effect on other types of kidney calculi remains unclear; thus, the results of this meta-analysis should be interpreted with caution; (4) some of the included studies assessed experimental groups and control groups with other measures as diet, fluid therapy or potassium chloride, which may be a source of heterogeneity; and (5) we only described the adverse reactions qualitatively and didn't conduct meta-analysis of the safety of thiazide diuretics for recurrent kidney calculi.

Conclusions {#Sec20}
===========

Long-term use of thiazide diuretics can reduce the incidence of recurrent renal calculi and 24-h urinary calcium level. However, the benefits are insufficient, and the quality of evidence is low. Considering the adverse effects, patients' preferences, and economic burden of long-term medication, we do not recommend the use of thiazide diuretics to prevent recurrent kidney calculi.
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**Additional file 1: Table S1.** Search strategy of PubMed.

RCT

:   Randomized controlled trial

RR

:   Relative risk

RD

:   Risk difference

SMD

:   Standardized mean difference

CI

:   Confidence interval
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